Fc Receptor-like 5 and Anti-CD20 Treatment Response in Granulomatosis with Polyangiitis and Microscopic Polyangiitis

Overview

Journal JCI Insight

Specialties Biomedical Engineering
General Medicine

Date 2020 Aug 26

PMID 32841219

Citations 5

Authors

Kasia Owczarczyk

Matthew D Cascino

Cecile Holweg

Gaik W Tew

Ward Ortmann

Timothy Behrens

Thomas Schindler

Carol A Langford

E William St Clair

Peter A Merkel

Robert Spiera

Philip Seo

Cees Gm Kallenberg

Ulrich Specks

Noha Lim

John Stone

Paul Brunetta

Marco Prunotto

Affiliations

Soon will be listed here.

Abstract

BACKGROUNDBaseline expression of FCRL5, a marker of naive and memory B cells, was shown to predict response to rituximab (RTX) in rheumatoid arthritis. This study investigated baseline expression of FCRL5 as a potential biomarker of clinical response to RTX in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).METHODSA previously validated quantitative PCR-based (qPCR-based) platform was used to assess FCRL5 expression in patients with GPA/MPA (RAVE trial, NCT00104299).RESULTSBaseline FCRL5 expression was significantly higher in patients achieving complete remission (CR) at 6, 12, and 18 months, independent of other clinical and serological variables, among those randomized to RTX but not cyclophosphamide-azathioprine (CYC/AZA). Patients with baseline FCRL5 expression ≥ 0.01 expression units (termed FCRL5hi) exhibited significantly higher CR rates at 6, 12, and 18 months as compared with FCRL5lo subjects (84% versus 57% [P = 0.016], 68% versus 40% [P = 0.02], and 68% versus 29% [P = 0.0009], respectively).CONCLUSIONOur data taken together suggest that FCRL5 is a biomarker of B cell lineage associated with increased achievement and maintenance of complete remission among patients treated with RTX and warrant further investigation in a prospective manner.FUNDINGThe analysis for this study was funded by Genentech Inc.

Citing Articles

Two Decades Rituximab Therapy in Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis.

Habibi M, Ahmadpour S, Tafaroji J, Eazi S, Mineaie P, Minaee P Curr Drug Targets. 2024; 26(2):73-87.

PMID: 39318005 DOI: 10.2174/0113894501323529240910015912.

New Biomarkers for Systemic Necrotizing Vasculitides.

Shumnalieva R, Ermencheva P, Kotov G, Parvova-Hristova I, Bakopoulou K, Kaouri I J Clin Med. 2024; 13(8).

PMID: 38673537 PMC: 11050764. DOI: 10.3390/jcm13082264.

Exploratory mass cytometry analysis reveals immunophenotypes of cancer treatment-related pneumonitis.

Yanagihara T, Hata K, Matsubara K, Kunimura K, Suzuki K, Tsubouchi K Elife. 2024; 12.

PMID: 38607373 PMC: 11014725. DOI: 10.7554/eLife.87288.

Mass cytometry identifies characteristic immune cell subsets in bronchoalveolar lavage fluid from interstitial lung diseases.

Hata K, Yanagihara T, Matsubara K, Kunimura K, Suzuki K, Tsubouchi K Front Immunol. 2023; 14:1145814.

PMID: 36949950 PMC: 10027011. DOI: 10.3389/fimmu.2023.1145814.

A comparison of rituximab with cyclophosphamide in terms of efficacy and complications as induction therapy for treating granulomatosis with polyangiitis: A three-center study.

Chaleshtori M, Farajzadegan Z, Salesi M Eur J Rheumatol. 2022; 9(2):88-92.

PMID: 35546333 PMC: 10176214. DOI: 10.5152/eurjrheum.2022.21063.

References

Unizony S, Villarreal M, Miloslavsky E, Lu N, Merkel P, Spiera R . Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann Rheum Dis. 2015; 75(6):1166-9. PMC: 4908815. DOI: 10.1136/annrheumdis-2015-208073. View

Hogan S, Falk R, Chin H, Cai J, Jennette C, Jennette J . Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med. 2005; 143(9):621-31. DOI: 10.7326/0003-4819-143-9-200511010-00005. View

Franco A, Damdinsuren B, Ise T, Dement-Brown J, Li H, Nagata S . Human Fc receptor-like 5 binds intact IgG via mechanisms distinct from those of Fc receptors. J Immunol. 2013; 190(11):5739-46. PMC: 3660407. DOI: 10.4049/jimmunol.1202860. View

Sullivan R, Kim C, Fontana M, Feeney M, Jagannathan P, Boyle M . FCRL5 Delineates Functionally Impaired Memory B Cells Associated with Plasmodium falciparum Exposure. PLoS Pathog. 2015; 11(5):e1004894. PMC: 4438005. DOI: 10.1371/journal.ppat.1004894. View

Terrier B, Nagata S, Ise T, Rosenzwajg M, Pastan I, Klatzmann D . CD21(-/low) marginal zone B cells highly express Fc receptor-like 5 protein and are killed by anti-Fc receptor-like 5 immunotoxins in hepatitis C virus-associated mixed cryoglobulinemia vasculitis. Arthritis Rheumatol. 2014; 66(2):433-43. PMC: 5823695. DOI: 10.1002/art.38222. View

Damdinsuren B, Dement-Brown J, Li H, Tolnay M . B cell receptor induced Fc receptor-like 5 expression is mediated by multiple signaling pathways converging on NF-κB and NFAT. Mol Immunol. 2016; 73:112-21. DOI: 10.1016/j.molimm.2016.04.001. View

Nasrallah M, Pouliot Y, Hartmann B, Dunn P, Thomson E, Wiser J . Reanalysis of the Rituximab in ANCA-Associated Vasculitis trial identifies granulocyte subsets as a novel early marker of successful treatment. Arthritis Res Ther. 2015; 17:262. PMC: 4576403. DOI: 10.1186/s13075-015-0778-z. View

Chang L, Li Y, Kaplan D . Hepatitis C viraemia reversibly maintains subset of antigen-specific T-bet+ tissue-like memory B cells. J Viral Hepat. 2016; 24(5):389-396. PMC: 5637374. DOI: 10.1111/jvh.12659. View

Haga C, Ehrhardt G, Boohaker R, Davis R, Cooper M . Fc receptor-like 5 inhibits B cell activation via SHP-1 tyrosine phosphatase recruitment. Proc Natl Acad Sci U S A. 2007; 104(23):9770-5. PMC: 1887609. DOI: 10.1073/pnas.0703354104. View

10.

Krumbholz M, Specks U, Wick M, Kalled S, Jenne D, Meinl E . BAFF is elevated in serum of patients with Wegener's granulomatosis. J Autoimmun. 2005; 25(4):298-302. DOI: 10.1016/j.jaut.2005.08.004. View

11.

Li H, Borrego F, Nagata S, Tolnay M . Fc Receptor-like 5 Expression Distinguishes Two Distinct Subsets of Human Circulating Tissue-like Memory B Cells. J Immunol. 2016; 196(10):4064-74. DOI: 10.4049/jimmunol.1501027. View

12.

Stone J, Merkel P, Spiera R, Seo P, Langford C, Hoffman G . Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010; 363(3):221-32. PMC: 3137658. DOI: 10.1056/NEJMoa0909905. View

13.

Stone J, Hoffman G, Merkel P, Min Y, Uhlfelder M, Hellmann D . A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum. 2001; 44(4):912-20. DOI: 10.1002/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5. View

14.

Owczarczyk K, Lal P, Abbas A, Wolslegel K, Holweg C, Dummer W . A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis. Sci Transl Med. 2011; 3(101):101ra92. DOI: 10.1126/scitranslmed.3002432. View

15.

Jennette J, Falk R . Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. Nat Rev Rheumatol. 2014; 10(8):463-73. DOI: 10.1038/nrrheum.2014.103. View

16.

Specks U, Merkel P, Seo P, Spiera R, Langford C, Hoffman G . Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. 2013; 369(5):417-27. PMC: 5953195. DOI: 10.1056/NEJMoa1213277. View